WFN service page.

World Federation of Neurology, Chester House, 83 Fulham High St, London SW6 3JA, London, UK; Medical University of Vienna, Ludwig Boltzmann Institute for Experimental und Clinical Traumatology Donaueschingenstraße, 13 A-1200 Wien, Austria. Electronic address:

William M Carroll Wolfgang Grisold

Unlabelled: The WFN Needs Registry survey was developed and conducted over two and a half years commencing in 2020 to investigate the accessibility and affordability of neurological services and therapeutics and the most urgent needs.

Method: An experienced neurologist responded in each of 118 societies to an online electronic survey comprising 13 questions. General data sought comprised the respondent's training, place of practice, duration in practice, number of neurologists in the society, health care system and types of neurological practice available.

View Article and Find Full Text PDF

Similar Publications

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

Lancet

August 2024

Novartis Pharma, Basel, Switzerland. Electronic address:

Benjamin A Fisher Xavier Mariette Athena Papas Thomas Grader-Beck Hendrika Bootsma

Background: Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in patients with active Sjögren's disease.

Methods: This randomised, double-blind, placebo-controlled, phase 2b study, conducted at 71 sites in 23 countries, enrolled patients aged 18 years or older fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) 2016 criteria.

View Article and Find Full Text PDF

Similar Publications